CMPS 6.47 COMPASS Pathways plc
| Range: | 5.01-12.75 | Vol Avg: | 509290 | Last Div: | 0 | Changes: | -0.03 |
| Beta: | 2.26 | Cap: | 0.41B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Sep 18 2020 | Empoloyees: | 186 | ||
| CUSIP: | 20451W101 | CIK: | 0001816590 | ISIN: | US20451W1018 | Country: | GB |
| CEO: | Mr. Kabir Kumar Nath M.A., M.B.A. | Website: | https://compasspathways.com | ||||
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow